Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Ovarian response to recombinant human follicle-stimulating hormone : a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. / Arce, Joan-Carles; Andersen, Anders Nyboe; Fernández-Sánchez, Manuel; Visnova, Hana; Bosch, Ernesto; García-Velasco, Juan Antonio; Barri, Pedro; de Sutter, Petra; Klein, Bjarke M; Fauser, Bart C J M.

I: Fertility and Sterility, Bind 102, Nr. 6, 12.2014, s. 1633-1640.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Arce, J-C, Andersen, AN, Fernández-Sánchez, M, Visnova, H, Bosch, E, García-Velasco, JA, Barri, P, de Sutter, P, Klein, BM & Fauser, BCJM 2014, 'Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection' Fertility and Sterility, bind 102, nr. 6, s. 1633-1640. https://doi.org/10.1016/j.fertnstert.2014.08.013

APA

Arce, J-C., Andersen, A. N., Fernández-Sánchez, M., Visnova, H., Bosch, E., García-Velasco, J. A., ... Fauser, B. C. J. M. (2014). Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility, 102(6), 1633-1640. https://doi.org/10.1016/j.fertnstert.2014.08.013

Vancouver

Arce J-C, Andersen AN, Fernández-Sánchez M, Visnova H, Bosch E, García-Velasco JA o.a. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility. 2014 dec;102(6):1633-1640. https://doi.org/10.1016/j.fertnstert.2014.08.013

Author

Arce, Joan-Carles ; Andersen, Anders Nyboe ; Fernández-Sánchez, Manuel ; Visnova, Hana ; Bosch, Ernesto ; García-Velasco, Juan Antonio ; Barri, Pedro ; de Sutter, Petra ; Klein, Bjarke M ; Fauser, Bart C J M. / Ovarian response to recombinant human follicle-stimulating hormone : a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. I: Fertility and Sterility. 2014 ; Bind 102, Nr. 6. s. 1633-1640.

Bibtex

@article{4800b46745b94b0c8b1d966f32d3fbca,
title = "Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antim{\"u}llerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection",
abstract = "OBJECTIVE: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antim{\"u}llerian hormone (AMH) concentrations.DESIGN: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial.SETTING: Seven infertility centers in four countries.PATIENT(S): Two hundred sixty-five women aged ≤37 years.INTERVENTION(S): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle.MAIN OUTCOME MEASURE(S): Number of oocytes retrieved.RESULT(S): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10{\%} increase in dose resulted in 0.5 (95{\%} confidence interval 0.2-0.7) and 1.0 (95{\%} confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum.CONCLUSION(S): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level.CLINICAL TRIAL REGISTRATION NUMBER: NCT01426386.",
keywords = "Adult, Anti-Mullerian Hormone, Female, Fertilization in Vitro, Follicle Stimulating Hormone, Human, Humans, Oocyte Retrieval, Ovulation Induction, Recombinant Proteins, Sperm Injections, Intracytoplasmic, Treatment Outcome",
author = "Joan-Carles Arce and Andersen, {Anders Nyboe} and Manuel Fern{\'a}ndez-S{\'a}nchez and Hana Visnova and Ernesto Bosch and Garc{\'i}a-Velasco, {Juan Antonio} and Pedro Barri and {de Sutter}, Petra and Klein, {Bjarke M} and Fauser, {Bart C J M}",
note = "Copyright {\circledC} 2014 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = "12",
doi = "10.1016/j.fertnstert.2014.08.013",
language = "English",
volume = "102",
pages = "1633--1640",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Ovarian response to recombinant human follicle-stimulating hormone

T2 - a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection

AU - Arce, Joan-Carles

AU - Andersen, Anders Nyboe

AU - Fernández-Sánchez, Manuel

AU - Visnova, Hana

AU - Bosch, Ernesto

AU - García-Velasco, Juan Antonio

AU - Barri, Pedro

AU - de Sutter, Petra

AU - Klein, Bjarke M

AU - Fauser, Bart C J M

N1 - Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2014/12

Y1 - 2014/12

N2 - OBJECTIVE: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antimüllerian hormone (AMH) concentrations.DESIGN: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial.SETTING: Seven infertility centers in four countries.PATIENT(S): Two hundred sixty-five women aged ≤37 years.INTERVENTION(S): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle.MAIN OUTCOME MEASURE(S): Number of oocytes retrieved.RESULT(S): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10% increase in dose resulted in 0.5 (95% confidence interval 0.2-0.7) and 1.0 (95% confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum.CONCLUSION(S): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level.CLINICAL TRIAL REGISTRATION NUMBER: NCT01426386.

AB - OBJECTIVE: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antimüllerian hormone (AMH) concentrations.DESIGN: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial.SETTING: Seven infertility centers in four countries.PATIENT(S): Two hundred sixty-five women aged ≤37 years.INTERVENTION(S): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle.MAIN OUTCOME MEASURE(S): Number of oocytes retrieved.RESULT(S): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10% increase in dose resulted in 0.5 (95% confidence interval 0.2-0.7) and 1.0 (95% confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum.CONCLUSION(S): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level.CLINICAL TRIAL REGISTRATION NUMBER: NCT01426386.

KW - Adult

KW - Anti-Mullerian Hormone

KW - Female

KW - Fertilization in Vitro

KW - Follicle Stimulating Hormone, Human

KW - Humans

KW - Oocyte Retrieval

KW - Ovulation Induction

KW - Recombinant Proteins

KW - Sperm Injections, Intracytoplasmic

KW - Treatment Outcome

U2 - 10.1016/j.fertnstert.2014.08.013

DO - 10.1016/j.fertnstert.2014.08.013

M3 - Journal article

VL - 102

SP - 1633

EP - 1640

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -

ID: 135501661